This article is more than 5 years old. Information may no longer be current.

VIDEO: Bibila reviews Merck's biosimilar accomplishments

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — At the American College of Rheumatology Annual Meeting, Dora Bibila PhD, general manager of biosimilars at Merck, reviewed the company’s accomplishments with biosimilars.

Through biosimilar research, there is an opportunity to increase space in health care budgets for new medicines in cancer and Alzheimer’s disease, Bibila said. To help physicians and patients feel more confident in biosimilars, Merck launched MerckClarifiesBiosimilars.com. Currently, Merck has launched Brenzys (Samsung Bioepis), an etanercept biosimilar, as well as Renflexis (Samsung Bioepis), an infliximab biosimilar.